Skip to content Skip to footer
Subscribe Now
NEWS

Ascidian and Eli Lilly Partner to Advance RNA Exon Editors for Devastating Kidney Diseases in a ~$1.9B Deal

Shots: Ascidian has entered a global research & licensing agreement with Eli Lilly to discover & develop therapies for undisclosed monogenic kidney diseases, with an option to expand the collaboration to additional targets As per the deal, Lilly will obtain exclusive target-specific rights to Ascidian’s RNA exon editing tech for undisclosed targets, with Ascidian leading…
June 3, 2026

Read more

NEWS

Haisco Enters ~$3.05B License and Research Collaboration with Lilly to Develop Novel Medicines Across Multiple Therapeutic Areas

Shots: Haisco Pharmaceutical has entered into a licensing & research collaboration with Eli Lilly to develop novel medicines across multiple therapeutic areas As per the deal, Haisco will be responsible for the discovery & identification of ~5 target programs, while Lilly will lead IND-enabling studies, clinical development, & commercialization Lilly will gain exclusive global rights…
June 1, 2026

Read more

Eli lilly
NEWS

Eli Lilly Highlights P-III (LIBRETTO-432) Trial Data on Retevmo for Early-Stage RET Fusion–Positive NSCLC at ASCO 2026

Shots: Lilly's global P-III (LIBRETTO-432) trial assessed Retevmo (selpercatinib; 160mg, BID) vs PBO in 151 pts with early-stage (IB-IIIA) RET fusion-positive NSCLC following completion of definitive radiotherapy or surgery with curative intent, & other adjuvant therapy Trial met the 1EP, improving the EFS by 83% in stage II–IIIA RET-positive NSCLC (n=109), with 24mos. EFS rates of…
June 1, 2026

Read more

NEWS

Hanmi Pharm Inks ~$1.26B Deal with Eli Lilly to Advance Sonefpeglutide

Shots: Hanmi Pharm has granted Eli Lilly exclusive global rights (excl. Korea) to develop, manufacture & commercialize sonefpeglutide, a GLP-2 analog incorporating Hanmi's long-acting platform tech, Lapscovery As per the deal, Hanmi will receive $75M upfront & up to $1.185B in clinical development, regulatory approval, and commercialization milestone payments, with royalties following product launch Hanmi…
June 1, 2026

Read more

NEWS

Eli Lilly Builds Infectious Disease Pipeline With 3 Acquisitions Valued ~$3.8B

Shots: Eli Lilly will acquire 3 companies, Curevo, LimmaTech Biologics, & Vaccine Company, to build its infectious disease portfolio through differentiated vaccine & platform technologies The deals incl. Curevo’s P-II shingles vaccine candidate amezosvatein, LimmaTech’s P-I vaccine LTB-SA7 targeting S. aureus infections, & Vaccine Company’s preclinical EBV vaccine platform leveraging proprietary in vivo nanoparticle technology As…
May 26, 2026

Read more

Eli lilly
NEWS

Eli Lilly Reports the P-Ib (Heart-2) Trial Data on VERVE-102 as a One-Time Treatment for Hypercholesterolemia

Shots: Trial assessed Lilly's VERVE-102 (IV; 0.3, 0.45, 0.6, 0.7, 0.8 & 1mg/kg) in 35 adults with HeFH or premature coronary artery disease who required additional LDL-C lowering despite maximally tolerated oral lipid-lowering therapy Single infusion of VERVE-102 led to dose-dependent PCSK9 reductions of 51% (0.3mg/kg) to 88% (1mg/kg), with corresponding mean LDL-C reductions of…
May 26, 2026

Read more

NEWS

Eli Lilly Acquires Engage Biologics for ~$202M

Shots: Eli Lilly has acquired Engage Biologics, combining Engage’s Tethosome platform with Lilly’s genetic medicines capabilities & portfolio As per the deal, Eli Lilly acquired Engage for ~$202M in cash, incl. an upfront payment and subsequent development milestones payments The Tethosome platform is a non-viral DNA delivery system that combines engineered DNA payloads, lipid nanoparticles,…
May 21, 2026

Read more

INSIGHTS+

The US FDA New Drug Approvals in April 2026 

Shots:  Approval activity continued strongly into April 2026, with the US FDA authorizing two significant therapies across metabolic disease and infectious disease, reinforcing the agency’s focus on chronic disease management, long-term treatment innovation, and broader patient access.  Two notable therapies achieved regulatory clearance: Eli Lilly’s Foundayo for weight loss in obese or overweight adults with weight-related conditions,…
May 12, 2026

Read more

Load more